Featured
Vertex Pharmaceuticals Reports Long-Term Durability of CRISPR Base Editing for Sickle Cell Disease and Beta-Thalassemia
Vertex Pharmaceuticals releases five-year follow-up data for exa-cel, the CRISPR-based gene-editing therapy for sickle cell disease and beta-thalassem...
Read Full Story →